| |
|
Product Name:
|
DSY562
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Classification: Mitosporic Saccharomycetales; Candida
Species: Candida glabrata (also referred to as Nakaseomyces glabrata and Nakaseomyces glabratus)1,2,3
Strain: DSY562
|
|
Additional Information:
|
C. glabrata are ubiquitous in the environment and commensal inhabitants of the oral cavity, gastrointestinal tract and skin of most healthy humans.6,7 For the immunocompromised, however, C. glabrata is the second most commonly recovered pathogenic yeast in the United States behind C. albicans. Together, the two species are responsible for approximately 70% of all cases of systemic candidiasis with increasing rates of multidrug resistance, particularly to azoles.4,5,6,7 C. glabrata is more closely related phylogenetically to Saccharomyces cerevisiae than C. albicans, and is a member of the Nakaseomyces clade. Unlike other Candida, C. glabrata has a haploid genome, and therefore only reproduces asexually, forming blastoconidia. In addition, C. glabrata has differentiating features such as absence of pseudohyphae, facultative anaerobic growth and rapidly decreasing susceptibility to azole antifungals.7,8,9
Reclassification of C. glabrata to Nakaseomyces glabratus has been proposed following a phylogenomic analysis of the genus Candida, and is currently under debate.1,2,3
|
|
Material Provided:
|
Each vial contains approximately 0.5 mL of yeast culture in 20% glycerol.
|
|
Packing/Storage:
|
NR-51685 was packaged aseptically in cryovials and is provided frozen on dry ice. The product should be stored at -70°C or colder. For long-term storage the product should be stored -130°C or colder, preferably in the vapor phase of a liquid nitrogen freezer.
|
|
Growth Conditions:
|
Media:
Yeast Mold broth or Emmons Modified Sabouraud broth or equivalent
Yeast Mold agar or Emmons Modified Sabouraud agar or equivalent
Incubation:
Temperature: 25°C to 30°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use; thaw rapidly in a water bath at 25°C to 30°C. Typically, this takes less than 5 minutes.
2. Immediately after thawing, inoculate an agar plate with approximately 50 µL of thawed culture and/or transfer the entire thawed aliquot into a single tube of broth.
3. Incubate the plate and/or tube at 25°C to 30°C for 2 to 6 days.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Takashima, M. and T. Sugita. “Taxonomy of Pathogenic Yeasts Candida, Cryptococcus, Malassezia, and Trichosporon.” Med. Mycol. J. 63 (2022): 119-132. PubMed: 36450564.
2. Beardsley, J., et al. “Candida glabrata (Nakaseomyces glabrata): Asystematic Review of Clinical and Microbiological Data from 2011 to 2021 to Inform the World Health Organization Fungal Priority Pathogens List.” Med. Mycol. 62 (2024): myae041. PubMed: 38935913.
3. Denning, D. W. “Renaming Candida glabrata – A Case of Taxonomic Purity over Clinical and Public Health Pragmatism.” PLoS Pathog. 20 (2024): e1012055. PubMed: 38489254.
4. Sanglard, D., et al. “The ATP Binding Cassette Transporter Gene CgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents.” Antimicrob. Agents Chemother. 43 (1999): 2753-2765. PubMed: 10543759.
5. Vale-Silva, L., et al. “Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates.” G3 (Bethesda) 7 (2017): 2413-2426. PubMed: 28663342.
6. Brunke, S. and B. Hube. “Two Unlike Cousins: Candida albicans and C. glabrata Infection Strategies.” Cell. Microbiol. 15 (2013): 701-708. PubMed: 23253282.
7. Hendrickson, J. A., et al. “Antifungal Resistance: A Concerning Trend for the Present and Future.” Curr. Infect. Dis. Rep. 21 (2019): 47. PubMed: 31734730.
8. Bolotin-Fukuhara, M. and C. Fairhead. “Candida glabrata: A Deadly Companion?” Yeast 8 (2014): 279-288. PubMed: 24861573.
9. Glockner, A. and O. A. Cornely. “Candida glabrata – Unique Features and Challenges in the Clinical Management of Invasive Infections.” Mycoses 58 (2015): 445-450. PubMed: 26207423.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Candida glabrata, Strain DSY562, NR-51685.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|